Nalbuphine extended-release reduces cough bouts in patients with idiopathic pulmonary fibrosis

This post-hoc analysis evaluated the effect of nalbuphine extended-release tablets on cough bouts (ie clusters of sequential coughs) in 38 patients with idiopathic pulmonary fibrosis who participated in a randomized, double-blind, placebo-controlled, Phase 2a crossover trial. Cough bouts at the beginning and the end of treatment were analyzed using 24-hour cough frequency data collected using the Vitalograph VitaloJAK digital cough monitor.